Enzyme Induction and Beta-adrenergic Receptor Blocking Drugs

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 1984 Jan 1

PMID 6146342

Citations 8

Authors

R A Branch

R J Herman

Affiliations

Soon will be listed here.

Abstract

All beta-adrenergic receptor blockers that require metabolism prior to elimination are potentially subject to drug interactions due to enzyme induction. However, data is only available in man for propranolol, metoprolol and alprenolol. Cross-sectional population studies suggest that environmental factors, such as smoking in the young, are able to influence the oral clearance of propranolol. Long-term studies comparing within-subject clearances of metoprolol, alprenolol and propranolol before and after rifampicin and pentobarbitone, indicate that oral clearance is increased by 50%-500%. Inducing agents can influence intrinsic clearance, liver blood flow, and protein binding in addition to drug metabolising ability, indicating that changes in pharmacokinetic disposition may be complex. Enzyme induction exhibits both dose and time dependency relationships. The maximal extent of enzyme induction is similar between subjects. The range of intersubject variation in drug metabolism is similar before and after induction. The reduction in steady-state beta-adrenergic receptor drug concentration following enzyme induction is sufficiently large that an altered pharmacodynamic response would be expected if no dosage modification is made.

Citing Articles

Management of Drug Interactions with Inducers: Onset and Disappearance of Induction on Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyltransferase 1A1 Substrates.

Bettonte S, Berton M, Stader F, Battegay M, Marzolini C Eur J Drug Metab Pharmacokinet. 2023; 48(4):353-362.

PMID: 37278880 PMC: 10322778. DOI: 10.1007/s13318-023-00833-9.

Inhibition and induction of cytochrome P450 and the clinical implications.

Lin J, Lu A Clin Pharmacokinet. 1998; 35(5):361-90.

PMID: 9839089 DOI: 10.2165/00003088-199835050-00003.

The induction effect of rifampicin on activity of mephenytoin 4'-hydroxylase related to M1 mutation of CYP2C19 and gene dose.

Feng H, Huang S, Wang W, Zhou H Br J Clin Pharmacol. 1998; 45(1):27-9.

PMID: 9489590 PMC: 1873992. DOI: 10.1046/j.1365-2125.1998.00643.x.

Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update.

Riddell J, Harron D, Shanks R Clin Pharmacokinet. 1987; 12(5):305-20.

PMID: 2886244 DOI: 10.2165/00003088-198712050-00001.

Clinical pharmacokinetic considerations in the elderly. An update.

Dawling S, Crome P Clin Pharmacokinet. 1989; 17(4):236-63.

PMID: 2686883 DOI: 10.2165/00003088-198917040-00003.

References

Vesell E, Page J . Genetic control of dicumarol levels in man. J Clin Invest. 1968; 47(12):2657-63. PMC: 297437. DOI: 10.1172/JCI105949. View

Vesell E, Page J . Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man. J Clin Invest. 1969; 48(12):2202-9. PMC: 297477. DOI: 10.1172/JCI106186. View

Ohnhaus E, Thorgeirsson S, Davies D, Breckenridge A . Changes in liver blood flow during enzyme induction. Biochem Pharmacol. 1971; 20(10):2561-70. DOI: 10.1016/0006-2952(71)90164-x. View

Breckenridge A, Orme M, Davies L, Thorgeirsson S, Davies D . Dose-dependent enzyme induction. Clin Pharmacol Ther. 1973; 14(4):514-20. DOI: 10.1002/cpt1973144part1514. View

Branch R, SHAND D, Wilkinson G, Nies A . Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow. J Clin Invest. 1974; 53(4):1101-7. PMC: 333095. DOI: 10.1172/JCI107647. View

Wilkinson G, SHAND D . Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975; 18(4):377-90. DOI: 10.1002/cpt1975184377. View

Gelehrter T . Enzyme induction (third of three parts). N Engl J Med. 1976; 294(12):646-51. DOI: 10.1056/NEJM197603182941206. View

Roberts C, Jackson L, Halliwell M, Branch R . The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man. Br J Clin Pharmacol. 1976; 3(5):907-13. PMC: 1428933. DOI: 10.1111/j.1365-2125.1976.tb00646.x. View

Breimer D, Zilly W, Richter E . Influence of rifampicin on drug metabolism: differences between hexobarbital and antipyrine. Clin Pharmacol Ther. 1977; 21(4):470-81. DOI: 10.1002/cpt1977214470. View

10.

Jusko W . Role of tobacco smoking in pharmacokinetics. J Pharmacokinet Biopharm. 1978; 6(1):7-39. DOI: 10.1007/BF01066061. View

11.

Collste P, Seideman P, Borg K, Haglund K, von Bahr C . Influence of pentobarbital on effect and plasma levels of alprenolol and 4-hydroxy-alprenolol. Clin Pharmacol Ther. 1979; 25(4):423-7. DOI: 10.1002/cpt1979254423. View

12.

Ohnhaus E, Park B . Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin. Eur J Clin Pharmacol. 1979; 15(2):139-45. DOI: 10.1007/BF00609878. View

13.

Vestal R, Wood A, Branch R, SHAND D, Wilkinson G . Effects of age and cigarette smoking on propranolol disposition. Clin Pharmacol Ther. 1979; 26(1):8-15. DOI: 10.1002/cpt19792618. View

14.

Branch R, SHAND D . A re-evaluation of intersubject variation in enzyme induction in man. Clin Pharmacokinet. 1979; 4(2):104-10. DOI: 10.2165/00003088-197904020-00003. View

15.

Sotaniemi E, Anttila M, Pelkonen R, Jarvensivu P, Sundquist H . Plasma clearance of propranolol and sotalol and hepatic drug-metabolizing enzyme activity. Clin Pharmacol Ther. 1979; 26(2):153-61. DOI: 10.1002/cpt1979262153. View

16.

Lu A, West S . Multiplicity of mammalian microsomal cytochromes P-45. Pharmacol Rev. 1979; 31(4):277-95. View

17.

Park B, Breckenridge A . Clinical implications of enzyme induction and enzyme inhibition. Clin Pharmacokinet. 1981; 6(1):1-24. DOI: 10.2165/00003088-198106010-00001. View

18.

Bennett P, John V, Whitmarsh V . Effect of rifampicin on metoprolol and antipyrine kinetics. Br J Clin Pharmacol. 1982; 13(3):387-91. PMC: 1402102. DOI: 10.1111/j.1365-2125.1982.tb01390.x. View

19.

Bai S, Abramson F . Interactions of phenobarbital with propranolol in the dog. 1. Plasma protein binding. J Pharmacol Exp Ther. 1982; 222(3):589-94. View

20.

Vu V, Bai S, Abramson F . Interactions of phenobarbital with propranolol in the dog. 2. Bioavailability, metabolism and pharmacokinetics. J Pharmacol Exp Ther. 1983; 224(1):55-61. View